- Source type
- Study
- Access type
- Publisher
- Publisher
- Nature Medicine
- Date
- 2024
- Added
- 2026-06-19
Trust profile
88
Peer-reviewed research publisher
- Publisher type
- Peer-reviewed journal
- Bias profile
- Moderate
Best used for
- Primary studies
- Systematic reviews
- Mechanistic research
Weak for
- Regulatory status
- Universal consumer recommendations
Used in Viral Vitalism
GLP-1s Are Not Just a Weight Loss Story
Roles: Primary source
Show section-level references
Claims supported
No reusable evidence claims are currently attached to this source.
Related studies
Related sources
FDA approves Wegovy to reduce risk of serious heart problems in adults with obesity or overweight and cardiovascular disease
U.S. Food and Drug Administration used across the Viral Vitalism evidence library.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 6 connections
SELECT trial: semaglutide and cardiovascular outcomes
PubMed used across the Viral Vitalism evidence library.
- Trust score
- 91
- Publisher
- PubMed
- Indexed by
- PubMed
- Access
- Abstract/index
- Usage
- 3 connections
Semaglutide and cardiovascular outcomes in obesity without diabetes
New England Journal of Medicine used across the Viral Vitalism evidence library.
- Trust score
- 88
- Publisher
- New England Journal of Medicine
- Access
- Publisher
- Usage
- 5 connections
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder
Trial registry for oral semaglutide among adults with AUD.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Does Semaglutide Reduce Alcohol Intake
Trial registry for semaglutide and alcohol intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 1 connection
Effects of Semaglutide on Nicotine Intake
Trial registry for semaglutide and nicotine intake.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 2 connections
